TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05992766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Description: Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hammock Yoga
Description: Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mat exercises
Description: The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
Study: NCT05533918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-Messaging (TM)
Description: Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN)
Description: Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types.
Study: NCT04239027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTH258/Brolucizumab
Description: Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye.
Study: NCT05884684

Intervention type: OTHER
Group type: OTHER
Intervention: Reviewing Imaging with Participant
Description: Post-operatively, the images taken during the procedure will be reviewed with the participant.
Study: NCT05707754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topically applied to sphenopalatine ganglion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topically applied to sphenopalatine ganglion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topically applied to sphenopalatine ganglion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topically applied to sphenopalatine ganglion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiocatheter
Description: Introduced into nose to reach sphenopalatine ganglion nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiocatheter
Description: Introduced into nose to reach sphenopalatine ganglion nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiocatheter
Description: Introduced into nose to reach sphenopalatine ganglion nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiocatheter
Description: Introduced into nose to reach sphenopalatine ganglion nerve
Study: NCT06343402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-8520
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-8520
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-8520
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBO-8520
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive IV pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive IV pembrolizumab
Study: NCT05467839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: derma pen
Description: Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
Study: NCT05888961

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interviewing the subject and scales
Description: Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviewing the subject and scales
Description: Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviewing the subject and scales
Description: Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviewing the subject and scales
Description: Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session
Study: NCT05985538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaping prevention text messages
Description: Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness behaviors text messages
Description: Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
Study: NCT05778123

Intervention type: OTHER
Intervention: Type of disease
Description: Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.

Intervention type: OTHER
Intervention: Type of disease
Description: Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
Study: NCT06371118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directly mailed self-sampling kit to collect a vaginal sample
Description: The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure
Description: Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care - screening in a clinical setting
Description: Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
Study: NCT06040008

Intervention type: GENETIC
Intervention: blood collection
Description: * 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit
Study: NCT05105412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 11)
Description: lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 21)
Description: lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 31)
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Gemcitabine (Dose level 41)
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
Study: NCT05616637

Intervention type: DIAGNOSTIC_TEST
Intervention: Navicular Drop Test
Description: While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.

Intervention type: OTHER
Intervention: Lower Extremity Length Measurement
Description: Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.

Intervention type: OTHER
Intervention: Y Balance Test
Description: While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
Study: NCT06421883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus containing probiotic
Description: Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months.
Study: NCT06130423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Music therapy carried out with Music Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study: NCT06328179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
Description: VHEA -Induction Phase Regimen/Consolidation therapy after remission
Study: NCT05857852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LIFU device
Description: Sham LIFU device administered in one of two sessions
Study: NCT05354466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex injection
Description: sugammadex as reversal agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine as a reversal agent
Study: NCT06310304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib IR
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib IR
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib XR
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib XR
Description: Tablet
Study: NCT05321641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone message reminders.
Description: Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
Study: NCT05289947

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caramel, chocolate brown, flavor (E_1982648), dextrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC1501
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC1501
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Study: NCT05060744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antacid
Description: The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
Study: NCT05391386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified bonding technique
Description: adding a layer of compomer adhesive at the molar/tube interface.
Study: NCT05327673

Intervention type: OTHER
Intervention: questionnaire
Description: * quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire

Intervention type: OTHER
Intervention: questionnaire
Description: * quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire
Study: NCT05758233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversalis fascia plane block
Description: The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversalis fascia plane block
Description: The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversus abdominis plane block
Description: The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing transversus abdominis plane block
Description: The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
Study: NCT05961501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An aqueous solution containing CBD and CBN
Description: An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The aqueous solution of placebo
Description: An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
Study: NCT05534386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer survivorship care intervention
Description: A one-off face-to-face assessment and personal advice by members of a multidisciplinary team

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-up targeted personalized intervention
Description: To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First stage control intervention
Description: A set of skill-based pamphlets will be given.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Second stage control intervention
Description: Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet